Drug
Siponimod clinical trials
Also written BAF312 and Mayzent.
- studies test it
- 15
- open now
- 1
- in phase 3
- 4
- first study started
- 2006
Keep track of what changes. Save the siponimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 2
Novartis Pharmaceuticals (12) · Novartis (1) · St. Joseph's Hospital and Medical Center, Phoenix (1) · State University of New York at Buffalo (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses siponimod is read from its arms, and is right about nine times in ten.
Testing it · 15
- Repurposing Siponimod for Alzheimer's DiseaseRecruitingPhase 2St. Joseph's Hospital and Medical Center, PhoenixNCT06639282Written as Siponimod
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04926818Written as Siponimod
- Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple SclerosisTerminatedPhase 2/3State University of New York at BuffaloNCT04925557Written as Mayzent
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedPhase 4Novartis PharmaceuticalsNCT04792567Written as BAF312
- Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03623243Written as Siponimod
- Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)CompletedPhase 3Novartis PharmaceuticalsNCT01665144Written as BAF312
- Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).CompletedPhase 2Novartis PharmaceuticalsNCT03338998Written as BAF312 solution
- Safety and Efficacy of BAF312 in DermatomyositisTerminatedPhase 2Novartis PharmaceuticalsNCT02029274Written as BAF312
- Efficacy and Tolerability of BAF312 in Patients With PolymyositisTerminatedPhase 2Novartis PharmaceuticalsNCT01801917Written as BAF312
- Pharmacokinetics of BAF312 in Patients With Hepatic ImpairmentCompletedPhase 1Novartis PharmaceuticalsNCT01565902Written as BAF312
- A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionCompletedPhase 1Novartis PharmaceuticalsNCT01904214Written as BAF312
- Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2Novartis PharmaceuticalsNCT00879658Written as BAF312
- Efficacy and Tolerability of BAF312 in Patients With Polymyositis and DermatomyositisTerminatedPhase 2Novartis PharmaceuticalsNCT01148810Written as BAF312
- Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedPhase 2Novartis PharmaceuticalsNCT01185821Written as BAF312
- Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312CompletedPhase 1NovartisNCT00422175Written as BAF 312
Given in every arm · 1 — siponimod is usual care beside what is tested
Codes
What other systems call siponimod · ClinicalTrials.gg INT006246
- MeSH (NLM) C578989siponimodConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RR6P8L282ISIPONIMODConfirmed FDA, NLM, Wikidata
- RxNorm 2121085One source FDA
- Wikidata Q25100876siponimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152368SiponimodOne source FDA
- DrugBank DB12371One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C578989 | siponimod | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RR6P8L282I | SIPONIMOD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2121085 | — | One source FDA |
| Wikidata | Q25100876 | siponimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152368 | Siponimod | One source FDA |
| DrugBank | DB12371 | — | One source Wikidata |
Also registered as siponimod fumaric acid (UNII Z7G02XZ0M6).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.